The standard treatment for GVHD, high dose steroids, offers less than optimal outcomes as well as significant toxicities. Better treatments, especially for GI GVHD, are needed to reduce non-relapse mortality after allogeneic HCT. The identification of high risk patients through a biomarker-defined scoring system offers a personalized approach to a disease that still requires significant research attention.
Keyphrases
- high dose
- end stage renal disease
- stem cell transplantation
- newly diagnosed
- ejection fraction
- chronic kidney disease
- liver failure
- low dose
- allogeneic hematopoietic stem cell transplantation
- prognostic factors
- type diabetes
- patient reported outcomes
- metabolic syndrome
- respiratory failure
- acute myeloid leukemia
- intensive care unit
- free survival
- signaling pathway
- hepatitis b virus
- patient reported
- hematopoietic stem cell
- glycemic control
- replacement therapy
- acute respiratory distress syndrome